RBCEV RNA Delivery for Low-Toxicity RIG-I Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for delivering RNA oligonucleotides, such as siRNAs, face inefficiencies in targeting cells and induce toxicity, leading to organ damage and reduced effectiveness due to off-target effects.
Innovation Solution
Development of vesicle-based compositions, including red blood cell-derived extracellular vesicles (RBCEVs) loaded with immunomodulatory RNA (immRNA) and antisense oligonucleotides, which utilize a 5' triphosphate cap for enhanced delivery and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If lipid-based nanoparticles are used to deliver siRNA, then toxicity is reduced, but off-target effects occur causing accumulation in wrong cells and decreased effectiveness
Solution Approach 1:
The patent uses red blood cell-derived extracellular vesicles (RBCEVs) as an intermediary delivery vehicle instead of conventional lipid-based nanoparticles. RBCEVs naturally target endothelial cells and are taken up by the reticuloendothelial system, providing inherent cell-type specificity that prevents off-target accumulation while maintaining low toxicity. This intermediary vehicle resolves the contradiction by simultaneously achieving safe delivery without effectiveness loss.
Solution Approach 2:
The patent applies local quality by loading specific RIG-I agonist oligonucleotides into RBCEVs that naturally home to particular cell types. The delivery system exhibits spatially selective distribution, concentrating the therapeutic agent precisely where needed (in target cells with endothelial or reticuloendothelial characteristics) while avoiding accumulation in wrong cells, thereby maintaining both low toxicity and high effectiveness.
2Productivity
If conventional delivery methods are used for RNA oligonucleotides, then delivery is achieved, but targeting efficiency is poor and toxicity increases
Solution Approach 1:
The patent employs RBCEVs that possess intrinsic targeting capabilities without requiring external modification or complex targeting ligands. The vesicles naturally home to endothelial cells and are cleared by the reticuloendothelial system, enabling self-directed delivery to specific cell populations. This self-service mechanism achieves high delivery efficiency to target cells while avoiding non-specific accumulation that causes toxicity.
Solution Approach 2:
The patent changes the fundamental parameter of the delivery vehicle from synthetic lipid nanoparticles to biologically-derived RBCEVs. This parameter change fundamentally alters the biodistribution profile, enabling natural targeting to specific cell types and reducing non-specific toxicity while maintaining effective delivery of the RNA oligonucleotide payload.
Data Source
AI summary
Disclosed are vesicle-based compositions and uses thereof. The composition comprising a vesicle, such as a red blood cell-derived extracellular vesicle (RBCEV), for delivery of a retinoic acid inducible gene I receptor (RIG-I) agonist to a cell. Also disclosed are methods for treating diseases by administering the vesicle-based compositions.